Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models

Ha-Yeon Shin 1, Eun-ju Lee 1, Wookyeom Yang 2, Hyo Sun Kim 1, Dawn Chung 1, Hanbyoul Cho 1 and Jae-Hoon Kim 1,*

1 Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Korea; hayeon37@yuhs.ac (H.-Y.S.); forgetme107@gmail.com (E.-j.L.); khs88@yuhs.ac (H.S.K.); dawny1004@yuhs.ac (D.C.); hanbyoul@yuhs.ac (H.C.)
2 Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 03722, Korea; wookyeom@yuhs.ac
* Correspondence: jaehoonkim@yuhs.ac; Tel.: +82-02-2019-3430

Simple Summary: As a preclinical model for personalized cancer therapy, the patient-derived xenograft (PDX) model is suitable because it provides the best representation of the original tumor, but it still has many limitations. We analyzed gynecologic cancer PDX models with their clinical information and gene expression profiling, and found that the success rate of PDX correlated with the patient’s tumor grade and prognosis. Moreover, we showed that the faster the tumor progressed in PDXs, the poorer the prognosis in ovarian cancer patients. We confirmed that the differentially expressed genes (DEGs) selected according to PDX engraftment status could be a prognosis marker of ovarian clear cell cancer patients. This study paves the way for a better application of the PDX in gynecologic cancer.

Abstract: Patient-derived xenografts (PDXs) are important in vivo models for the development of precision medicine. However, challenges exist regarding genetic alterations and relapse after primary treatment. Thus, PDX models are required as a new approach for preclinical and clinical studies. We established PDX models of gynecologic cancers and analyzed their clinical information. We subcutaneously transplanted 207 tumor tissues from patients with gynecologic cancer into nude mice from 2014 to 2019. The successful engraftment rate of ovarian, cervical, and uterine cancer was 47%, 64%, and 56%, respectively. The subsequent passages (P2 and P3) showed higher success and faster growth rates than the first passage (P1). Using gynecologic cancer PDX models, the tumor grade is a common clinical factor affecting PDX establishment. We found that the PDX success rate correlated with the patient’s prognosis, and also that ovarian cancer patients with a poor prognosis had a faster PDX growth rate (p < 0.0001). Next, the gene sets associated with inflammation and immune responses were shown in high-ranking successful PDX engraftment through gene set enrichment analysis and RNA sequencing. Up-regulated genes in successful engraftment were found to correlate with ovarian clear cell cancer patient outcomes via Gene Expression Omnibus dataset analysis.

Keywords: patient-derived xenograft; gynecologic cancer; prognostic markers

1. Introduction

Gynecologic cancers are defined as cancers occurring in the human female reproductive system, composed of internal and external sex organs [1]. Approximately 113,520 American women are diagnosed with gynecologic cancer each year, and 33,620 die every year as result of this cancer [2]. In Korea, the incidence rates for gynecologic cancers increased annually from 2005 until 2017. The 5-year relative survival rates from ovarian, cervical, and endometrial cancer were reported to be 61%, 81%, and 88%, respectively [3]. Gynecologic cancers frequently occur in postmenopausal women, with a high incidence rate in women...
aged 50–60 years [4,5]. However, in recent years, the incidence of gynecologic cancer has increased in women under the age of 39 and over the age of 80 [6]. Gynecologic cancer does not only occur in postmenopausal women; it can occur in women of all ages. The emergence of this cancer in a period of active living places an enormous burden on patients’ quality of life. Therefore, gynecologic cancer has become a major burden throughout women’s lives.

Comprehensive therapy for gynecologic cancer includes surgery, platinum/paclitaxel-based chemotherapy, and radiotherapy with intensity-modulated radiation therapy (IMRT) [4]. Recently, the application of various targeted therapies and immune checkpoint inhibitors has improved clinical outcomes [7–9]. However, there is still a need to improve therapy options for patients with advanced-stage disease. Theoretically, cervical cancers can be overcome through vaccination and regular screening, but many patients still miss the appropriate treatment time [10]. A new milestone in ovarian cancer therapy is thought to be the use of vascular endothelial growth factor inhibitors and poly (ADP-ribose) polymerase inhibitors in patients with homologous recombination deficiency [11]. However, evidence for biomarker-driven treatment is lacking. Moreover, as less than half of patients have non-homologous recombination deficiency, new drug therapies are required. Most endometrial cancers are treated successfully with surgical debulking alone [12]. Endometrial cancers can predict the prognosis of endometrioid adenocarcinoma through molecular classification, which can help determine adjuvant treatment [13,14]. However, the development of effective therapeutic agents for a small number of patients with advanced or recurrent disease is required. Therefore, it is necessary to determine the most effective and appropriate drugs for each patient.

Patient-derived xenografts (PDXs) are used to directly implant fresh tumor tissues from patients with cancer into immune-deficient mice. The advantages of PDX models are well-maintained tumor heterogeneity and tumor microenvironment, including cellular complexity, genomic, stromal architecture, and non-tumor cells [15–17]. Hence, the therapeutic effect of drugs is better evaluated by PDX models than by other in vivo models such as cell line xenografts, syngeneic models, and genetically engineered mouse models [18]. By applying PDX models to various cancers, we have observed that the tumor engraftment rate differs according to tumor type. PDXs have a high success rate for colorectal cancer (76–89%) and head and neck cancer (68–85%), but a low success rate for breast cancer (13–21%) and liver cancer (14%) [19]. The success rates of gynecologic cancers have been reported as 18.5–74%, 48–70%, and 60% in ovarian [20–22], cervical [23,24], and endometrial cancer [25], respectively. Moreover, the success rates have not been reported for rare gynecologic cancers, such as vaginal and vulvar cancers [26].

Initially, PDX models were designed to screen anti-cancer drugs for personalized medicine. This is because PDX tumor tissues have similar clinicopathological characteristics for each patient [27–29]. However, such efforts were soon challenged because it was uncertain whether the PDX establishment was successful, and a substantial period of time was also required before drug testing [30]. We often encountered cases in which the disease progressed before the patient’s PDX model was completed, and the treatment time was missed, or the patient’s disease relapsed and had different characteristics, making PDX models ineffective. Henceforth, we need a comprehensive database of PDX characteristics and the efficacy of various anticancer drugs on PDX. The reason is that it is possible to quickly identify a drug with good effect in the PDX model most similar to the patient’s tumor via this database when a patient is diagnosed with cancer.

According to previous reports, various factors influence the establishment of PDX, but more aggressive and poor prognostic types show a higher PDX success rate. These phenomena tend to be consistent regardless of tumor origin [21,31,32]. Based on these phenomena, the prognosis of patients can be predicted by comparing gene expression alterations between cancer tissues in PDX engraftment success and failure. This study aimed to establish various gynecological PDX models and identify clinicopathological factors influencing PDX establishment from patient clinical information. Additionally, we
evaluated whether the differentially expressed genes (DEGs) according to PDX engraftment status could predict patient prognosis.

2. Materials and Methods

2.1. Patients and Tissue Specimens

This study was approved by the Institutional Review Board of Gangnam Severance Hospital (3-2014-0184; Seoul, Korea). A total of 207 patients with gynecologic cancer from 2014 to 2019 were enrolled in this study. The experiments were performed with each patient’s understanding and written consent, following the Declaration of Helsinki. After tumor surgery, the specimens were immediately sectioned. To establish PDX models, a portion was transferred to the laboratory under transport media with 1% penicillin/streptomycin, 5 μg/mL tetracycline, and 10 μg/mL ciprofloxacin. A portion was quickly submitted for formalin-fixed paraffin embedding, and other portions were stocked with preservation solution, RNAlater™ (Invitrogen, Carlsbad, USA), or without RNAlater™ at −150 °C or −80 °C.

2.2. Engraftment and Management of PDX Models

For engraftment in mice, the animal experiments were approved by the Institutional Animal Care and Use Committee at Yonsei University (2014-0273, 2018-0047; Seoul, Korea). The tumors sectioned to approximately 3 mm³ were subcutaneously transplanted into at least two female 5- to 6-week-old BALB/c nude mice (four subcutaneous transplants per mouse). First, the mice were anesthetized by injection of a 100 µL mixture of Zoletil/Rompun/DDW (1:1:7 ratio). The surgery site on each flank of the nude mice was disinfected with povidone-iodine pads and 70% isopropyl alcohol swabs. The site was incised, a piece of tissue was implanted, and finally, the site was sutured using a stitching fiber. The tumor size was evaluated using a digital caliper. The tumor volume was calculated using the formula: Volume = (Width² × length) × 0.5. We observed tumor growth for one year. When the size of the biggest tumor among the tumors implanted and growing in the mice was over 100 mm³, we defined it as successful engraftment. The xenograft tumors engrafted into mice from patient-derived tumors were defined as P1. After that, xenograft tumors serially engrafted into the next mice were termed as P2 to P3. We collected and banked small pieces of tumor tissue from each passage of PDX tissue.

2.3. Tumor Growth Rate

We calculated tumor growth rate because the time required for growth and tumor volume differs for each PDX tumor.

\[
\text{Tumor growth rate} = \frac{\text{Final tumor volume (mm}^3\text{)}}{\text{Duration (month)}}
\]  

Final tumor volumes are to be measured just before mice are sacrificed for the next passage. Here, duration implies a period of development of PDX from tissue transplantation to the next passage.

2.4. Gene Set Enrichment Analysis (GSEA) and Gene Clustering

GSEA was performed to identify DEGs that were enriched in the gene lists extracted from MSigDB3 [33].

2.5. Histologic and Immunohistochemical Analysis

Tissues were fixed overnight in 10% formalin and processed in the tissue core facility at the Mayo Clinic. To compare with the histopathologic features of tumor tissue, both human and mouse tumor tissues were divided into 10 um sections and stained with hematoxylin and eosin (H & E). For immunohistochemistry, deparaffinized and rehydrated 10 um sections were retrieved in pH 6.0, or 9.0 citrate buffer (Agilent Technologies, Inc., Santa Clara, CA, USA). Then, the sections were inactivated of endogenous peroxidase
with 3% hydrogen peroxide (Duksan, Seoul, Korea) and incubated with 5% BSA. Next, the cells were incubated with the primary antibody for 1 h at room temperature. The secondary antibody was applied for 30 min at room temperature, followed by detection using 3,3′-diaminobenzidine chromogen solution (Agilent Technologies, Inc.). The sections were mounted.

2.6. Antibodies

The primary antibodies used for immunohistochemistry were as follows. The anti-NFKB2 antibody (#15503-1-AP), anti-RELB antibody (#10544), and anti-ICOSLG antibody (TA808779) were purchased from Proteintech Group (Rosemont, IL, USA), Cell Signaling (Danvers, MA, USA), and ORIGENE (Rockville, MD, USA), respectively.

2.7. Statistical Analysis

Unpaired t-tests and Fisher’s exact tests were used to evaluate the differences between the two groups. The chi-square test was used to evaluate differences between three or more groups. Survival curve analysis was performed using the Kaplan–Meier method, and statistical significance was calculated using the log-rank test and the Gehan–Breslow–Wilcoxon test. All analyses were performed using the GraphPad Prism 9 software (GraphPad Software, San Diego, USA). Differences were considered significant at *p < 0.05, **p < 0.01, ***p < 0.001.

3. Results

3.1. PDX Models Improved the Success Rate of Tumor Engraftment and Growth Rate with Increased In Vivo Passage

To establish PDX models of gynecologic cancer, we tested ovarian cancer (n = 130), cervical and vaginal cancer (n = 45), and uterine cancer (n = 32) (Table 1). In the transplantation of the patient tumor to mice, successful engraftment rates of ovarian cancer, cervical and vaginal, and uterine cancer showed 46.92%, 64.44%, and 56.25% success rates, respectively. It took 5–7 months for the growth of the tumors in the mice. As the next mice were passaged, the tumor engraftment rate increased, and the duration required for engraftment was shortened. Moreover, the tumor growth rate increased depending on PDX passage in ovarian and uterine cancers but did not change in cervical and vaginal cancers. Next, we confirmed that the established PDX models maintained the histology of the original tumor via H&E staining (Supplementary Figure S1).
Table 1. Comparison of tumor engraftment and tumor growth rate according to the development of patient-derived xenograft models.

| Diagnosis                        | Successful Engraftment Rate (%) | Successful Engraftment | Failed Engraftment | p Value \(^a\) | Duration \(^b\) (Month) | p Value \(^c\) | Tumor Growth Rate \(^b\) | p Value \(^d\) |
|----------------------------------|---------------------------------|-------------------------|-------------------|-----------------|-------------------------|----------------|--------------------------|-----------------|
| Ovarian cancer, \(n\)            |                                 |                         |                   |                 |                         |                 |                          |                 |
| P1                               | 46.92                           | 61                      | 69                | <0.0001         | 6.70 ± 3.95            | 0.0021         | 319.3 ± 319.7            | reference       |
| P2                               | 90.16                           | 55                      | 6                 | 0.0004          | 4.93 ± 3.55            | 0.0145         | 575.1 ± 613.3            | 0.0168          |
| P3                               | 94.55                           | 52                      | 3                 | 0.0004          | 4.09 ± 2.85            |                | 527.5 ± 457.9            |                 |
| Cervical and Vaginal cancer, \(n\) |                                 |                         |                   |                 |                         |                 |                          |                 |
| P1                               | 64.44                           | 29                      | 16                | 0.7828          | 5.42 ± 2.74            |                | 606.7 ± 527.0            | reference       |
| P2                               | 89.66                           | 26                      | 3                 | 0.5891          | 3.19 ± 1.57            |                | 558.7 ± 594.6            |                 |
| P3                               | 100                             | 26                      | 0                 | 0.5891          | 3.10 ± 1.61            |                | 525.2 ± 394.5            |                 |
| Uterine cancer, \(n\)            |                                 |                         |                   |                 |                         |                 |                          |                 |
| P1                               | 56.25                           | 18                      | 14                | 0.0144          | 6.04 ± 4.13            | 0.08           | 427.3 ± 507.2            | reference       |
| P2                               | 94.44                           | 17                      | 1                 | 0.8992          | 4.11 ± 3.15            |                | 449.8 ± 339.0            |                 |
| P3                               | 76.47                           | 13                      | 4                 | 0.0341          | 2.80 ± 1.48            |                | 1208 ± 1204              |                 |

\(^a\) Chi-square test values for success and failure. \(^b\) Values are mean ± standard derivation. \(^c\) One-way ANOVA test among P1, P2, and P3. \(^d\) Unpaired t-test values for growth rate of P2 or P3 compared to P1.
3.2. Tumor Grade has a Decisive Effect on the Engraftment of PDX Tissues

To identify factors affecting PDX engraftment, we analyzed engraftment (P1) and the growth rate of PDX (P1) according to the clinical information of gynecologic cancers. First, we confirmed that cancer antigen 125 (CA-125), a blood marker for ovarian cancer, was significantly elevated in patients with ovarian cancer with successful PDX but not in those with failed PDX (Table 2, \( p = 0.0216 \)). Borderline tumors did not have a good engraftment success rate, but invasive epithelial ovarian cancer accounted for the most successful cases, with 54 of 112 (48.21%) cases being successful. The success rate of PDX in epithelial ovarian cancer is affected by the cell type, stage, and tumor grade. We confirmed that cases with a higher stage (\( p = 0.0004 \)) and worse grade (\( p = 0.0073 \)) had a much greater PDX success rate. In addition, the growth rate of PDX tumors was faster in the late stage than in the early stage (\( p = 0.0002 \)). The number of non-epithelial ovarian cancers that attempted to establish PDX was small (\( n = 8 \)), but PDX models were established for germ cells and metastatic cell types (Table 2). In cervical cancer, P1 engraftment showed a success rate of 62.79% (27 of 43 cases), and vaginal cancers were attempted in two cases, both of which were successful. The PDX success rate of cervical cancer and vaginal cancer was also higher with poorer tumor differentiation (\( p = 0.0073 \)), but there was no difference according to cell type, stage, tumor growth rate, and squamous cell carcinoma antigen (SSC Ag) (Table 3). Finally, in uterine cancer, 18 of 32 cases were successful (56.25%), and the PDX success rate depended on tumor grade (\( p = 0.0025 \)), but there was no correlation with other factors (Table 4). In conclusion, we found that the common clinical factor influencing the establishment of PDX was tumor grade, regardless of tumor histotype.

### Table 2. Clinicopathological characteristics of patients with ovarian cancer according to P1 tumor engraftment status.

| Variables                                | Case | Successful Engraftment | Failed Engraftment | \( p \) Value | Tumor Growth Rate \(^a\) | \( p \) Value \(^d\) |
|------------------------------------------|------|------------------------|--------------------|---------------|---------------------------|------------------|
| All, \( n \)                            | 130  | 61                     | 69                 | 0.9706        | N/A                       | N/A              |
| Age (year) \(^a\)                       | 52.12±12.22 | 52.08±12.51          | 52.16±12.05       | 0.0216        | 942.7±2315                | 475.4±942.7     |
| Pre CA-125 level (U/mL) \(^a\)          | 942.7±2315 | 1442±3124              | 475.4±942.7       | 0.0216        | 942.7±2315                | 475.4±942.7     |
| Borderline tumors, \( n \)              | 10   | 2                      | 8                  | 1.0000        | N/A                       | N/A              |
| Histology, \( n \) (\%)                 |      |                        |                    |               |                           |                  |
| Serous                                  | 2 (20.00) | 0 (0.0)                | 2 (25.00)          | N/A           | 167.55±102.2              | N/A              |
| Mucinous                                | 8 (80.00) | 2 (100)                | 6 (75.00)          | N/A           | 167.55±102.2              | N/A              |
| Malignant tumors, \( n \)               | 120  | 59                     | 61                 | 0.0389        | 300.9±248.3               | reference        |
| Epithelial ovarian cancer, \( n \)      | 112  | 54                     | 58                 | N/A           | N/A                       | N/A              |
| Histology, \( n \) (\%)                 |      |                        |                    |               |                           |                  |
| Serous                                  | 68 (60.71) | 39 (72.22)            | 29 (50.00)         | 0.0389        | 300.9±248.3               | reference        |
| Clear                                   | 17 (15.18) | 6 (11.11)              | 11 (18.97)         | 0.6088        | 395.4±383.1               | <0.0001          |
| Endometrioid                            | 7 (6.25)  | 2 (3.70)               | 5 (8.62)           | <0.0001       | 373.5±322.0               | 0.807            |
| Mucinous                                | 12 (10.71) | 2 (3.70)               | 10 (17.24)         | 0.059         | 632.7±696.4               | N/A              |
| MMMT                                    | 7 (6.25)  | 5 (9.26)               | 2 (3.45)           | N/A           | N/A                       | N/A              |
| Brenner                                 | 1 (0.89)  | 0 (0.0)                | 1 (1.72)           | N/A           | N/A                       | N/A              |
Table 2. Cont.

| Variables                          | Case | Successful Engraftment | Failed Engraftment | p Value | Tumor Growth Rate \(^a\) | p Value \(^d\) |
|-----------------------------------|------|------------------------|--------------------|---------|--------------------------|----------------|
| Stage, n (%)                      |      |                        |                    |         |                          |                |
| I                                 | 27 (24.11) | 5 (9.26)               | 22 (37.93)         | 0.0004 \(^c\) | 112.6 \(\pm\) 53.89 | reference |
| II/III/IV/Recurrent Grade, n (%)  | 85 (75.89) | 49 (90.74)             | 36 (62.07)         | 0.0073 \(^c\) | 359.3 \(\pm\) 335.1 | 0.002         |
| 1                                 | 8 (7.14)     | 0 (0.0)                | 8 (13.79)          |         |                          |                |
| 2                                 | 10 (8.93)    | 7 (12.96)              | 3 (5.17)           |         |                          |                |
| 3                                 | 70 (62.50)   | 37 (68.52)             | 33 (56.90)         |         |                          |                |
| Unknown                           | 24 (21.43)   | 10 (18.52)             | 14 (24.14)         |         |                          |                |
| Non-Epithelial ovarian cancer, n  |      |                        |                    |         |                          |                |
| Histology, n (%)                  |      |                        |                    |         |                          |                |
| Sex                               |      |                        |                    |         |                          |                |
| Germ cell                         | 5 (62.50)    | 3 (60.00)              | 2 (66.67)          |         |                          | 84.12 \(\pm\) 106.3 |
| Metastatic                        | 2 (25.00)    | 2 (40.00)              | 0 (0.0)            |         |                          | N/A            |
| Stage, n (%)                      |      |                        |                    |         |                          |                |
| I                                 | 5 (62.50)    | 2 (40.00)              | 3 (10.00)          | 0.1964 \(^c\) | 159.25 | N/A |
| II/III/IV/Recurrent Grade, n (%)  | 3 (37.50)    | 3 (60.00)              | 0 (0.0)            | 8.98 | | |

\(^a\) Values are mean \(\pm\) standard derivation. \(^b\) Unpaired t-test for success and failure. \(^c\) Chi-square test or Fisher’s exact test values for success and failure. \(^d\) Unpaired t-test with Welch’s correction. Unknown data was excluded in calculation of p value. N/A, not applicable.

Table 3. Clinicopathological characteristics of patients with cervical or vaginal cancer according to P1 tumor engraftment status.

| Variables                          | Case | Successful Engraftment | Failed Engraftment | p Value | Tumor Growth Rate \(^a\) | p Value \(^e\) |
|-----------------------------------|------|------------------------|--------------------|---------|--------------------------|----------------|
| All, n                            | 45   | 29                     | 16                 |         |                          |                |
| Age (year) \(^a\)                 | 48.86 \(\pm\) 11.70 | 49.04 \(\pm\) 10.64 | 48.56 \(\pm\) 13.73 | 0.8991 \(^c\) | 603.9 \(\pm\) 548 | reference |
| SCC Ag (ng/mL) \(^a\)             | 15.05 \(\pm\) 33.27 | 13.74 \(\pm\) 18.15 | 17.68 \(\pm\) 52.87 | 0.7225 \(^c\) | 639.8 \(\pm\) 183 | 0.8532 |
| Diagnosis, n (%)                  |      |                        |                    |         |                          |                |
| Cervical cancer                   | 43 (95.56) | 27 (93.10)             | 16 (100)           | 0.5313  \(^d\) | 603.9 \(\pm\) 548 | reference |
| Vaginal cancer                    | 2 (4.45)     | 2 (6.90)               | 0 (0.0)            | 0.2238  \(^d\) | 639.8 \(\pm\) 183 | 0.8532 |
| Histology, n (%)                  |      |                        |                    |         |                          |                |
| Squamous                          | 32 (75.86)   | 22 (75.86)             | 10 (62.5)          | 0.7551  \(^d\) | 667.7 \(\pm\) 570.9 | reference |
| Adeno                             | 9 (20.00)     | 6 (20.69)              | 3 (18.75)          |         |                          | 399.0 \(\pm\) 326.8 | 0.1936 |
| Others                            | 4 (8.89)      | 1 (3.45)               | 3 (18.75)          |         |                          | 424.4 | N/A |
| Stage, n (%)                      |      |                        |                    |         |                          |                |
| I/II                              | 20 (44.45)   | 12 (41.38)             | 8 (50.00)          | 0.0073  \(^d\) | 591.6 \(\pm\) 495.3 | reference |
| III/IV/Recurrent Grade, n (%)     | 20 (55.00)   | 17 (58.62)             | 8 (50.00)          |         |                          | 617.8 \(\pm\) 566.0 | 0.9013 |

\(^a\) Values are mean \(\pm\) standard derivation. \(^b\) Others include two cases of adenosquamous carcinoma, two cases of mucinous. \(^c\) Unpaired t-test for success and failure. \(^d\) Fisher’s exact test or chi-square test. \(^e\) Unpaired t-test with Welch’s correction. Unknown data was excluded in calculation of p value. N/A, not applicable.
Table 4. Clinicopathological characteristics of patients with uterine cancer according to P1 tumor engraftment status.

| Variables                        | Case | Successful Engraftment | Failed Engraftment | \( p \) Value | Tumor Growth Rate \( ^a \) | \( p \) Value \( ^e \) |
|----------------------------------|------|------------------------|--------------------|---------------|-----------------------------|---------------------|
| All, \( n \)                     | 32   | 18                     | 14                 | 0.2032        | 288.4 ± 342.9              | reference           |
| Age (year) \( ^a \)              | 56.44 ± 10.01 | 58.44 ± 8.361 | 53.86 ± 11.60 | 0.4880        | 429.5 ± 532.7               | 0.7091              |
| Pre CA-125 level (U/mL) \( ^a \) | 477.7 ± 1574 | 307.7 ± 914.9 | 740.3 ± 2286    | 0.1595        | 338.2                       | N/A                 |
| Histology, \( n \) (%)          |      |                        |                    |               | 1127 ± 1088                 | 0.476               |
| Endometrioid                     | 22 (68.75) | 10 (55.56) | 12 (85.71)       | 288.4 ± 342.9 | reference                   |                     |
| Serous                           | 5 (15.63) | 4 (22.22) | 1 (7.14)         | 429.5 ± 532.7 | 0.7091                      |                     |
| Clear                            | 1 (3.13) | 1 (5.56) | 0 (0.0)          | 338.2         | N/A                         |                     |
| Carcinosarcoma                   | 3 (9.38) | 3 (16.67) | 0 (0.0)          | 1127 ± 1088   | 0.476                       |                     |
| Other \( ^b \)                   | 1 (3.13) | 0 (0.0) | 1 (7.14)         | N/A           | N/A                         |                     |
| Stage, \( n \) (%)              |      |                        |                    | 1.0000        | 363.9 ± 559.0               | reference           |
| I/II                             | 23 (71.88) | 13 (72.22) | 10 (71.43)       | 363.9 ± 559.0 | reference                   |                     |
| III/IV/Recurrent Grade, \( n \) (%) | 9 (28.13) | 5 (27.28) | 4 (28.57)       | 617.8 ± 275.4 | 0.2565                      |                     |
| 1                                | 4 (12.50) | 0 (0) | 4 (12.50)        | N/A           | N/A                         |                     |
| 2                                | 13 (40.63) | 5 (15.63) | 8 (25.00)       | 330.1 ± 477.3 | reference                   |                     |
| 3                                | 11 (34.38) | 10 (31.25) | 1 (3.16)        | 358.4 ± 293.8 | 0.919                       |                     |
| Unknown                          | 4 (12.50) | 3 (9.38) | 1 (3.16)        | 966.4 ± 1316  | N/A                         |                     |

\( ^a \) Values are mean ± standard derivation. \( ^b \) Other includes endometrial stromal sarcoma. \( ^c \) Unpaired t-test for success and failure. \( ^d \) Fisher’s exact test or chi-square test. \( ^e \) Unpaired t-test with Welch’s correction. Unknown data was excluded in calculation of \( p \) value. N/A, not applicable.

3.3. PDX Engraftment Rate and Tumor Growth Rates Correlate with Poor Prognosis

To confirm the correlation between the prognosis of patients and P1 tumor engraftment and growth rates, we evaluated the overall survival of patients according to tumor engraftment status. First, the overall survival of patients with ovarian cancer was worse in the successful PDX group than in the failed group (HR = 2.107, \( p = 0.0371 \)) (Figure 1A). As a result of prognostic analysis of epithelial ovarian cancer, which accounts for 85~90% of ovarian cancer [34], it was found that the successful group had a poor prognosis. However, there was no difference within Stage III patients (Supplementary Figure S2A,B). The overall survival of patients with cervical cancer tended to be poorer in the successful PDX group than in the failed group. However, these results were not statistically significant (HR = 4.333, \( p = 0.0774 \)) (Figure 1B). In contrast, there was no change in the overall survival of patients with uterine cancer (Figure 1C). Furthermore, we analyzed the overall survival according to the PDX tumor growth rate (P1). The prognosis was worse in patients with ovarian cancer with fast tumor growth than in those with slow tumor growth (Figure 2A). Notably, the same prognostic results were shown when only the epithelial ovarian cancer and Stage III cancers were targeted (Supplementary Figure S2C,D). In contrast, there was no association between patients’ survival and tumor tissue engraftment in cervical, vaginal, or uterine cancers (Figure 2B,C). These results suggest that the PDX success rate and tumor growth rate are associated with a poor prognosis in ovarian cancer.
Figure 1. Overall survival of patients based on tumor engraftment status. Overall survival of patients with ovarian cancer (A), cervical and vaginal cancer (B), and uterine cancer (C) in the success groups and failed groups of P1. Kaplan–Meier survival analysis was carried out, and log–rank p–values, HR, and CI are shown for each of the results. HR: hazard ratio; CI: confidence interval.

Figure 2. Overall survival of patients based on tumor growth rate. Overall survival of patients with ovarian cancer (A), cervical and vaginal cancer (B), and uterine cancer (C) in the slow and fast groups of P1 tumors. Kaplan–Meier survival analysis was carried out, log–rank p–values, HR, and CI are shown for each of the results. HR: hazard ratio; CI: confidence interval.
3.4. Inflammation and Immune Response Genes Correlate with the PDX Establishment Rate

To identify genes that influenced the establishment of PDX, we analyzed the differentially expressed genes (DEGs) using RNA sequencing data from ovarian cancer tissues (GSE157153). GSE157153 is a patient tissues dataset of clear-cell-type ovarian cancer registered with the Gene Expression Omnibus, which we reported previously [35]. Among the cancer tissues of GSE157153, the tissues of four patients with clear cell ovarian cancer concurred with cancer tissues to establish PDXs (Table 5). Two patient tissues were successfully engrafted, but the others failed. To select DEGs between the tissues with PDX success and failure, we performed GSEA. As a result, we obtained 50 hallmark gene sets from GSEA, and 24 gene sets were correlated with the successful PDX group. Notably, the high-ranking gene sets were related to inflammation and immune responses (Figure 3A). We confirmed the list of upregulated genes of TNFA_SIGNALING_VIA_NFKB, including NFKB, which is the most important regulator of the inflammatory response, using a heatmap (Figure 3B). They showed higher mRNA expression in the successful tissues than in the PDX-failed tissues. To evaluate the protein levels in the tissues, we performed immunohistochemistry for three genes: NFKB2, RELB, and ICOSLG. This confirmed that the protein levels of NFKB2, RELB, and ICOSLG were higher in the success group than in the failure group (Figure 3C). Therefore, these results indicate that PDX engraftment is positively correlated with inflammation- and immune-response-related genes, and that the identified genes can influence the PDX engraftment rate.

Table 5. Four patients belonging to both PDX and GSE157153.

| Patient NO. | Diagnosis | Histology | Age | Stage | GSE157153 | P1 Tumor Engraftment |
|------------|-----------|-----------|-----|-------|-----------|----------------------|
| 03         | ovarian cancer | clear cell | 47  | R     | GSM4756750 | Success              |
| 33         | ovarian cancer | clear cell | 32  | I C   | GSM4756737 | Success              |
| 52         | ovarian cancer | clear cell | 41  | IV    | GSM4756755 | Failed               |
| 83         | ovarian cancer | clear cell | 44  | IA    | GSM4756757 | Failed               |

R: recurrent.

3.5. Up-Regulated Genes in Successful Engraftment Are Associated with a Poor Prognosis of Patients with Ovarian Clear Cell Cancer

We extracted only ovarian clear cell cancer (n = 37) from gene expression profiling results (GSE73614) and carried out Kaplan–Meier analysis about up-regulated genes in successful engraftment of PDXs. The Kaplan–Meier curves indicated that the overall survival tends to be unfavorable in high-NFKB2-expression patients, but this was not validated by the statistics (Figure 4A), nor did the RELB expression affect overall survival (Figure 4B). Patients with high ICOSLG expression have a significantly poorer prognosis than those with low expression of ICOSLG (p = 0.0448) (Figure 4C). Our findings showed that the DEGs obtained according to PDX engraftment status could be potential targets to the prognosis marker of ovarian clear cell cancer patients.
Figure 3. Analysis of DEGs between successful and failed tumor engraftment in patient tissues. (A) GSEA of RNA-sequencing data for clear cell ovarian cancers with successful engraftment \((n = 2)\) versus failed engraftment \((n = 2)\) from the GSE157153 dataset. (B) Heatmap presents up-regulated DEG lists in TNFA_SIGNALING_VIA_NFKB gene set. (C) Immunohistochemistry of NFKB2, RELB, and ICOSLG in tissues of patients with clear cell ovarian cancer with successful engraftment or failed engraftment. Immunohistochemistry images show two parts of each tissue \((\times 400)\). DEG: differentially expressed genes; GSEA: gene set enrichment analysis.
were developed most recently. Human cell and tissue transplantation are more commonly performed using NOG mice than other mouse models because NOG mice have defects in certain innate immune functions, including NK cell dysfunction, low cytokine production, and T and B cell dysregulation [40]. NOG mice are immunodeficient grade by genetic modifications. Athymic nude mice have a mutation at the Foxn1 (winged-helix/forkhead transcription factor) gene, which blocks thymus-derived immune cell production. SCID, NOD/SCID, and NOG according to their genetic modifications.

Since nude mice were introduced in 1966 [39], immunodeficient mouse models have been continuously improved, including athymic nude, SCID, NOD/SCID, and NOG according to immune-defected grade by genetic modifications. Athymic nude mice have a mutation at the Foxn1 (winged-helix/forkhead transcription factor) gene, which blocks thymus-derived T cell production, but have highly activated NK cells. SCID mice have a mutation in Prkdcscid (protein kinase, DNA activated, catalytic polypeptide) gene and a lack of mature B and T lymphocytes. NOD/SCID mice show many innate immune defects, including NK cell dysfunction, low cytokine production, and T and B cell dysregulation [40]. NOG mice were developed most recently. Human cell and tissue transplantation are more commonly performed using NOG mice than other mouse models because NOG mice have defects in certain innate immune functions. NOD/SCID mice have low malignancy potential and limited occurrence, respectively.

Although few cases of borderline tumor and vaginal cancer were included, we established PDX models of these tumors, which have low malignancy potential and limited occurrence, respectively.

Patient-derived tumor xenograft (PDX) models retain certain characteristics of each patient, such as gene mutations, gene expression profiling, and pathological features [15]. In addition, they accurately replicate the results of corresponding therapies received by patients [36]. Therefore, PDX models have many roles in precision medicine, and many gynecologic cancer PDX models have also been established for preclinical or clinical research [29].

We attempted subcutaneous transplantation of more than 200 gynecologic cancer cases to BALB/c nude mice, suggesting a PDX success rate similar to the rate reported in previous studies [37]. Although few cases of borderline tumor and vaginal cancer were included, we established PDX models of these tumors, which have low malignancy potential and limited occurrence, respectively.

It is essential to use immunodeficient mice for the establishment of PDX models because the genetic background of mice is a crucial factor influencing PDX success [38]. Since nude mice were introduced in 1966 [39], immunodeficient mouse models have been continuously improved, including athymic nude, SCID, NOD/SCID, and NOG according to immune-defected grade by genetic modifications. Athymic nude mice have a mutation at the Foxn1 (winged-helix/forkhead transcription factor) gene, which blocks thymus-derived T cell production, but have highly activated NK cells. SCID mice have a mutation in Prkdcscid (protein kinase, DNA activated, catalytic polypeptide) gene and a lack of mature B and T lymphocytes. NOD/SCID mice show many innate immune defects, including NK cell dysfunction, low cytokine production, and T and B cell dysregulation [40]. NOG mice were developed most recently. Human cell and tissue transplantation are more commonly performed using NOG mice than other mouse models because NOG mice have defects in certain innate immune functions.

3.5. Up-Regulated Genes in Successful Engraftment are Associated with Poor Prognosis

We extracted only ovarian clear cell cancer cases from gene expression profiling and carried out Kaplan–Meier survival analysis; log-rank p-values, HR, and CI are shown for each of the results. HR: hazard ratio; CI: confidence interval.

4. Discussion

Patient-derived tumor xenograft (PDX) models retain certain characteristics of each patient, such as gene mutations, gene expression profiling, and pathological features [15]. In addition, they accurately replicate the results of corresponding therapies received by patients [36]. Therefore, PDX models have many roles in precision medicine, and many gynecologic cancer PDX models have also been established for preclinical or clinical research [29].

We attempted subcutaneous transplantation of more than 200 gynecologic cancer cases to BALB/c nude mice, suggesting a PDX success rate similar to the rate reported in previous studies [37]. Although few cases of borderline tumor and vaginal cancer were included, we established PDX models of these tumors, which have low malignancy potential and limited occurrence, respectively.

It is essential to use immunodeficient mice for the establishment of PDX models because the genetic background of mice is a crucial factor influencing PDX success [38]. Since nude mice were introduced in 1966 [39], immunodeficient mouse models have been continuously improved, including athymic nude, SCID, NOD/SCID, and NOG according to immune-defected grade by genetic modifications. Athymic nude mice have a mutation at the Foxn1 (winged-helix/forkhead transcription factor) gene, which blocks thymus-derived T cell production, but have highly activated NK cells. SCID mice have a mutation in Prkdcscid (protein kinase, DNA activated, catalytic polypeptide) gene and a lack of mature B and T lymphocytes. NOD/SCID mice show many innate immune defects, including NK cell dysfunction, low cytokine production, and T and B cell dysregulation [40]. NOG mice were developed most recently. Human cell and tissue transplantation are more commonly performed using NOG mice than other mouse models because NOG mice have defects in certain innate immune functions.
in T cells, B cells, and NK cells [41]. However, NOG mice greatly increase the cost of the PDX model study. The success rates of the PDX model in gynecologic cancer in NOG showed a 46.7% success rate [37]. PDX success rates in SCID mice are 74% for ovarian cancer and 48–70% for cervical cancer [22–24]. Our results confirmed a 52% success rate of PDX models in BALB/c nude mice, suggesting that PDX models of gynecologic cancer did not correspond with the success rate of cancer tissue transplantation in previously reported immunodeficient grades. Therefore, establishing PDX using BALB/c nude mice in this study might reduce costs and increase effectiveness.

We obtained the hallmark gene sets for gene alterations between successful and failed PDX tissues using GSEA. Upregulated gene sets in successful PDX tissue showed the signal pathways of “immune and inflammation response: “allograft_rejection”, “TNFA_signaling via_NFKB”, “interferon_GAMMA_response”, “interferon_alpha_response”, “inflammatory_response”, and “IL2_STAT5_SIGNALING”. These results suggest that PDX engraftment status distinguishes the gene expression pattern associated with patients’ immunity and inflammation. The results of GSEA, the nuclear factor kappa-light-chain-enhancer of activated B cell (NF-KB) pathways within an upregulated gene set, could be correlated with tissue engraftment and growth. NF-kB signaling is activated by tumor necrosis (TNF), IL-1, and toll-like receptor ligands. NF-kB is a protein complex that controls the gene transcription involved in “cell proliferation and survival,” “epithelial to mesenchymal transition,” invasion, angiogenesis, metastasis, and inflammation-related genes [42,43]. Additionally, NF-kB regulates cell adhesion molecules that promote tumor growth and metastasis in cancer cells [44]. The high expression of adhesion molecules E-selectin, VCAM-1, and ICAM-1 by NF-kB activation assists the attachment of white blood cells to the stimulated endothelial cell surface [45,46]. According to a report, NF-kB signaling appears to be highly activated in cancer-associated fibroblasts (CAFs), consisting of tumor microenvironments. Here, the tumor growth delay by inhibiting NF-kB activation was examined in a xenograft model [47,48]. PDX models can reenact the tumor microenvironment; in these models, activation of NF-kB is considered to have an important role in tissue growth. The upregulation of adhesion molecules by activating NF-kB could have positive effects on the engraftment of patient tissue to mouse subcutaneous tissues in the early stages of tissue transplantation.

We confirmed that PDX engraftment rate and tumor growth rates correlate with poor prognosis in ovarian cancer. Based on this, we considered that DEGs with high expression in the tumor of ovarian clear cell patients engrafted successfully could be potential prognosis markers. ICOSLG predicted overall survival with ovarian clear cell cancer via the Kaplan–Meier curve in our study. Unfortunately, our results did not check the role of NFKB2 and RELB, but previous reports showed they could be candidates as prognosis markers. NFKB2 is reportedly associated with poor ovarian cancer [49]. Moreover, the loss of RELB in mouse xenograft models using ovarian cancer cell lines significantly decreased chemoresistance, tumorigenesis, and ALDH expression and activity [50,51]. We suggest that a new prognosis marker can develop from the DEGs obtained according to PDX engraftment status.

There are two limitations to the interpretation of the results of this study. First, we performed our experiments for five years to establish the PDX models, but we did not statistically validate the overall survival from cervical and vaginal, and uterine cancer due to the small number of patients. Second, GESA analysis was conducted in only four cases with clear cell ovarian cancer in this study. To overcome these limitations, we will continue establishing PDX models and further collect gene profiling from various subtypes of cancer. Accordingly, we expect to obtain significant data from all gynecologic cancer types with ovarian cancer.

5. Conclusions

Our study concluded that immune- and inflammation-related genes are strongly associated with ovarian cancer PDX engraftment rate. In addition, they can predict the survival of patients with ovarian cancer. Further studies are needed to characterize patients’
cancer tissues, including corresponding PDX cancer tissues, utilizing sequencing technology. The gynecologic cancer PDX tissues that we established might be crucial to validate and evaluate anti-cancer drug responses in patients who develop cancer in the future.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14030829/s1, Figure S1: PDX tumors maintain the histology of their corresponding original tumors. Representative image of hematoxylin and eosin (H & E) staining of tumors from ovarian cancer, cervical cancer, and uterine cancer (×200). Figure S2: Overall survival of patients based on P1 tumor engraftment status with epithelial ovarian cancer (A), Stage III epithelial ovarian cancer (B). Overall survival of patients based on P1 tumor growth rate with epithelial ovarian cancer (C), epithelial ovarian cancer Stage III. Kaplan–Meier survival analysis was carried out; log-rank p-values, a Gehan–Breslow–Wilcoxon test, HR, and CI are shown for each of the results. HR: hazard ratio; CI: confidence interval

Author Contributions: Conceptualization, H.-Y.S. and J.-H.K.; methodology, H.-Y.S. and E.-j.L.; formal analysis, H.-Y.S. and W.Y.; investigation, H.-Y.S. and E.-j.L.; data curation, H.S.K., D.C. and H.C.; writing—original draft preparation, H.-Y.S.; writing—review and editing, J.-H.K. and W.Y.; supervision, J.-H.K. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2019R1A6A3A13092928, NRF-2021R1A2BS02001915). The research was performed with the support of The Health Fellowship Foundation.

Institutional Review Board Statement: This study was approved by the Institutional Review Board of Gangnam Severance Hospital (3-2014-0184; Seoul, Republic of Korea).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Sa, J.K.; Hwang, J.R.; Cho, Y.J.; Ryu, J.Y.; Choi, J.J.; Jeong, S.Y.; Kim, J.; Kim, M.S.; Paik, E.S.; Lee, Y.Y.; et al. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. *Genome Biol.* 2019, 20, 253. [CrossRef] [PubMed]
2. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. *CA A Cancer J. Clin.* 2020, 70, 7–30. [CrossRef] [PubMed]
3. Ha, H.I.; Chang, H.K.; Park, S.J.; Lim, J.; Won, Y.J.; Lim, M.C. The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry. *Obstet. Gynecol. Sci.* 2021, 64, 444–453. [CrossRef] [PubMed]
4. Min Chul, C. Management of Gynecologic Malignancies in the Elderly Women. *JCC* 2018, 19, 81–88. [CrossRef]
5. Furau, G.; Dascau, V.; Furau, C.; Paiuson, L.; Radu, A.; Stanescu, C. Gynecological Cancer Age Groups at the “Dr. Salvator Vuia” Clinical Obstetrics and Gynecology Hospital during the 2000-2009 Period. *Maedica* 2011, 6, 268–271.
6. Lim, M.C.; Won, Y.J.; Ko, M.J.; Kim, M.; Shim, S.H.; Suh, D.H.; Kim, J.W. Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999-2015. *J. Gynecol. Oncol.* 2019, 30, e38. [CrossRef]
7. Wang, Q.; Peng, H.; Qi, X.; Wu, M.; Zhao, X. Targeted therapies in gynecological cancers: A comprehensive review of clinical evidence. *Signal Transduct. Target. Ther.* 2020, 5, 137. [CrossRef]
8. Burger, R.A.; Brady, M.F.; Bookman, M.A.; Fleming, G.F.; Monk, B.J.; Huang, H.; Mannel, R.S.; Homesley, H.D.; Fowler, J.; Greer, B.E.; et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N. Engl. J. Med.* 2011, 365, 2473–2483. [CrossRef]
9. Perren, T.J.; Swart, A.M.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; Kurzeder, C.; et al. A phase 3 trial of bevacizumab in ovarian cancer. *N. Engl. J. Med.* 2011, 365, 2484–2496. [CrossRef]
10. Tewari, K.S.; Monk, B.J. Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2019, 37, 2472–2489. [CrossRef]
11. Kurnit, K.C.; Fleming, G.F.; Lengyel, E. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. *Obstet. Gynecol.* 2021, 137, 108–121. [CrossRef] [PubMed]
12. Miller, R.E.; Lewis, A.J.; Powell, M.E. PARP inhibitors and immunotherapy in ovarian and endometrial cancers. *Br. J. Radiol.* 2021, 94, 20210002. [CrossRef]
13. Kandoth, C.; Schultz, N.; Cherniack, A.D.; Akbani, R.; Liu, Y.; Shen, H.; Robertson, A.G.; Pashtan, I.; Shen, R.; Benz, C.C.; et al. Integrated genomic characterization of endometrial carcinoma. *Nature* 2013, 497, 67–73. [CrossRef] [PubMed]
14. Creutzberg, C.L.; Lu, K.H.; Fleming, G.F. Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2019, 37, 2490–2500. [CrossRef] [PubMed]
15. Rosfjord, E.; Lucas, J.; Li, G.; Gerber, H.P. Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology. Biochem. Pharmacol. 2014, 91, 135–143. [CrossRef] [PubMed]
16. Siolas, D.; Hannon, G.J. Patient-derived tumor xenografts: Transforming clinical samples into mouse models. Cancer Res. 2013, 73, 5315–5319. [CrossRef] [PubMed]
17. Aparicio, S.; Hidalgo, M.; Kung, A.L. Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 2015, 15, 311–316. [CrossRef] [PubMed]
18. Shaw, T.J.; Senterman, M.K.; Dawson, K.; Crane, C.A.; Vanderhyden, B.C. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther. J. Am. Soc. Gene Ther. 2004, 10, 1032–1042. [CrossRef] [PubMed]
19. Cho, S.Y. Patient-derived xenografts as compatible models for precision oncology. Lab. Anim. Res. 2020, 36, 14. [CrossRef] [PubMed]
20. Eoh, K.J.; Chung, Y.S.; Lee, S.H.; Park, S.A.; Kim, H.J.; Yang, W.; Lee, I.O.; Lee, Y.J.; Cho, H.; Chay, D.B.; et al. Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models. Cancer Res. Treat. 2018, 50, 956–963. [CrossRef] [PubMed]
21. Heo, E.J.; Cho, Y.J.; Cho, W.C.; Hong, J.E.; Jeon, H.K.; Oh, D.Y.; Choi, Y.L.; Song, S.Y.; Choi, J.J.; Bae, D.S.; et al. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. Cancer Res. Treat. 2017, 49, 915–926. [CrossRef]
22. Weroha, S.J.; Becker, M.A.; Enderica-Gonzalez, S.; Harrington, S.C.; Oberg, A.L.; Maurer, M.J.; Perkins, S.E.; AllHilli, M.; Butler, K.A.; McKinstry, S.; et al. Xenografts as in vivo surrogates for women with ovarian cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2014, 20, 1288–1297. [CrossRef]
23. Hoffmann, C.; Bachran, C.; Stenke, J.; Elezukurtaj, S.; Kaufmann, A.M.; Fuchs, H.; Loddenkemper, C.; Schneider, A.; Cichon, G. Creation and characterization of a xenograft model for human cervical cancer. Gynecol. Oncol. 2010, 118, 76–80. [CrossRef]
24. Scott, C.L.; Mackay, H.J.; Haluska, P., Jr. Patient-derived xenograft models in gynecologic malignancies. Am. Soc. Clin. Oncol. Educ. Book. Am. Soc. Clin. Oncology. Annu. Meet. 2014, e258–e266. [CrossRef]
25. Depreeuw, J.; Hermans, E.; Schrauwen, S.; Annibali, D.; Coenegrachts, L.; Thomas, D.; Luyckx, M.; Gutierrez-Roelens, I.; Debruyne, D.; Konings, K.; et al. Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. Gynecol. Oncol. 2015, 139, 118–126. [CrossRef]
26. Löhmussaar, K.; Boretto, M.; Clevers, H. Human-Derived Model Systems in Gynecological Cancer Research. Trends Cancer 2020, 6, 1031–1043. [CrossRef] [PubMed]
27. Wang, Z.; Fu, S.; Zhao, J.; Zhao, W.; Shen, Z.; Wang, D.; Duan, J.; Bai, H.; Wan, R.; Yu, J.; et al. Transbrachonchoplastic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. Cancer Lett. 2019, 440–441, 180–188. [CrossRef] [PubMed]
28. Owonikoko, T.K.; Zhang, G.; Kim, H.S.; Stinson, R.M.; Bechara, R.; Zhang, C.; Chen, Z.; Saba, N.F.; Pakkala, S.; Pillai, R.; et al. Patient-derived xenografts faithfully replicated clinical outcome in a phase II clinical trial of arsenic trioxide in relapsed small cell lung cancer. J. Transl. Med. 2016, 14, 111. [CrossRef]
29. Jiang, W.; Xie, S.; Liu, Y.; Zou, S.; Zhu, X. The Application of Patient-Derived Xenograft Models in Gynecologic Cancers. J. Cancer 2020, 11, 5478–5489. [CrossRef] [PubMed]
30. Zhang, F.; Wang, W.; Long, Y.; Liu, H.; Cheng, J.; Guo, L.; Li, R.; Meng, C.; Yu, S.; Zhao, Q.; et al. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. Cancer Commun. 2018, 38, 60. [CrossRef]
31. Chen, Q.; Wei, T.; Wang, J.; Zhang, Q.; Li, J.; Zhang, N.I.; Li, W.; Yang, Y.; Bai, X.; Liang, T. Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer. Pancreatology 2020, 20, 485–492. [CrossRef]
32. Xu, W.; Zhao, Z.Y.; An, Q.M.; Dong, B.; Ly, A.; Li, C.P.; Guan, X.Y.; Tian, X.Y.; Wu, J.H.; Hao, C.Y. Comprehensive comparison of patient-derived xenograft models in Hepatocellular Carcinoma and metastatic Liver Cancer. Int. J. Mol. Sci. 2020, 17, 3073–3081. [CrossRef] [PubMed]
33. Subramaniam, A.; Tamayo, P.; Mootha, VK.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Land, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [CrossRef] [PubMed]
34. Torre, L.A.; Trabert, B.; DeSantis, C.E.; Miller, K.D.; Samimi, G.; Runowicz, C.D.; Gaudet, M.M.; Jemal, A.; Siegel, R.L. Ovarian cancer statistics, 2018. CA A Cancer J. Clin. 2018, 68, 284–296. [CrossRef] [PubMed]
35. Shin, H.Y.; Yang, W.; Chay, D.B.; Lee, E.J.; Chung, J.Y.; Kim, H.S.; Kim, J.H. Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma. Mol. Oncol. 2021, 15, 987–1004. [CrossRef] [PubMed]
36. Izumchenko, E.; Paz, K.; Ciznadija, D.; Sloma, I.; Katz, A.; Vasquez-Dunddel, D.; Ben-Zvi, I.; Stebbing, J.; McGuire, W.; Harris, W.; et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017, 28, 2595–2605. [CrossRef] [PubMed]
37. Yang, W.; Fan, W.S.; Ye, M.X.; Li, Z.; Gu, C.L.; Zhu, Y.P.; Hao, Y.P.; Wang, Z.Q.; Wang, L.; Meng, Y.G. Establishment of the PDTX model of gynecological tumors. Am. J. Transl. Res. 2019, 11, 3779–3789. [PubMed]
38. Goto, T. Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine. J. Pers. Med. 2020, 10, 64. [CrossRef] [PubMed]
39. Flanagan, S.P. ‘Nude’ a new hairless gene with pleiotropic effects in the mouse. Genet. Res. 1966, 8, 295–309. [CrossRef] [PubMed]
40. Belizário, J.E.J.T.O.I.J. Immunodeficient Mouse Models: An Overview. Open Immunol. J. 2009, 2, 79–85. [CrossRef]
41. Collins, A.T.; Lang, S.H. A systematic review of the validity of patient derived xenograft (PDX) models: The implications for translational research and personalised medicine. PeerJ 2018, 6, e5981. [CrossRef]
42. Taniguchi, K.; Karin, M. NF-κB, inflammation, immunity and cancer: Coming of age. Nat. Rev. Immunol. 2018, 18, 309–324. [CrossRef]
43. Xia, Y.; Shen, S.; Verma, I.M. NF-κB, an active player in human cancers. Cancer Immunol. Res. 2014, 2, 823–830. [CrossRef] [PubMed]
44. Harjunpää, H.; Llort Asens, M.; Guenther, C.; Fagerholm, S.C. Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment. Front. Immunol. 2019, 10, 1078. [CrossRef] [PubMed]
45. Xia, Y.F.; Liu, L.P.; Zhong, C.P.; Geng, J.G. NF-kappaB activation for constitutive expression of VCAM-1 and ICAM-1 on B lymphocytes and plasma cells. Biochem. Biophys. Res. Commun. 2001, 289, 851–856. [CrossRef] [PubMed]
46. Collins, T.; Read, M.A.; Neish, A.S.; Whitley, M.Z.; Thanos, D.; Maniatis, T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 1995, 9, 899–909. [CrossRef]
47. Erez, N.; Truitt, M.; Olson, P.; Arron, S.T.; Hanahan, D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell 2010, 17, 135–147. [CrossRef]
48. Huang, W.; Zhang, L.; Yang, M.; Wu, X.; Wang, X.; Huang, W.; Yuan, L.; Pan, H.; Wang, Y.; Wang, Z.; et al. Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-κB pathway. J. Exp. Clin. Cancer Res. 2021, 40, 87. [CrossRef]
49. Hufnagel, D.H.; Wilson, A.J.; Saxon, J.; Blackwell, T.S.; Watkins, J.; Khabele, D.; Crispens, M.A.; Yull, F.E.; Beeghly-Fadiel, A. Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis. Biomark. Res. 2020, 8, 45. [CrossRef]
50. House, C.D.; Jordan, E.; Hernandez, L.; Ozaki, M.; James, J.M.; Kim, M.; Kruhlak, M.J.; Batchelor, E.; Elloumi, F.; Cam, M.C.; et al. NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH(+) Cancer Stem-like Cells. Cancer Res. 2017, 77, 6927–6940. [CrossRef]
51. Harrington, B.S.; Annunziata, C.M. NF-κB Signaling in Ovarian Cancer. Cancers 2019, 11, 1182. [CrossRef]